C. Durante

Journal of Clinical Endocrinology and Metabolism · 2006–2019

A researcher in the Science corpus: 4 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Papers from C. Durante's perspective

Ordered by how strongly the researchers C. Durante trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Extent of Surgery Affects Survival for Papillary Thyroid Cancer (Annals of Surgery)
  2. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. (European Journal of Endocrinology)
  3. Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer
  4. Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase 3 trial (The Lancet)
  5. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. (Journal of Clinical Endocrinology and Metabolism)
  6. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). (European Journal of Cancer)
  7. Second primary malignancies in thyroid cancer patients (British Journal of Cancer)
  8. The Bethesda System for Reporting Thyroid Cytopathology (Cambridge International Law Journal)
  9. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. (New England Journal of Medicine)
  10. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma (JAMA Oncology)

Their papers